September - 2015
| Previous Past Months | Showing Journal 9 of 9 |
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionN. Galie?, J.A. Barbera?, A.E. Frost, H.-A. Ghofrani, for the AMBITION Investigators New Eng J Med, 2015, 373:834-844 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
September |
Previous Comments
No Comments yet.
Comment
Current therapies for pulmonary arterial hypertension target abnormalities in one of three intracellular pathways with signalling dysfunction: the prostacyclin, nitric oxide, or endothelin pathway. No single class of agent treats all patients,...